Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179647 · ClinicalTrials.gov registry record · Phase 3
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
A Phase 3 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,913
- Enrollment target
NCT00179647 is a Phase 3 study that has completed, run by Celgene Corporation. The registered enrollment target is 1,913 participants.
The verdict
NCT00179647, a Phase 3 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,913 participants
- Enrollment target
Study Summary
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Interventions
- DRUG dexamethasone
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,913 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179647
The ClinicalTrials.gov registry entry for NCT00179647 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,913 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00179647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179647 about?
NCT00179647 is a clinical study titled "Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma". Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
What is the current status of trial NCT00179647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,913 participants. The study started on 2005-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00179647?
The interventions under investigation include: dexamethasone (DRUG), lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00179647?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.